Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2021
This is a randomized, double-blind, single center, phase 2 study to assess efficacy and safety of multiple allogeneic HB-adMSCs vs Placebo for the treatment of Parkinson\'s disease.
Epistemonikos ID: 21e26379d2b73aba718b50d7f544c8b9a6f6779e
First added on: Oct 02, 2023